Hansa Biopharma Announces Upcoming Presentations at the 2019 American Transplant Congress
Lund, Sweden, May 2, 2019 - Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that IDEFIRIX (imlifidase), the Company’s novel IgG-degrading enzyme, will be highlighted in three presentations at the upcoming 2019 American Transplant Congress (ATC), which will be held from June 1 – 5, 2019 in Boston, Massachusetts, USA.In a plenary session on June 5, 2019 at 8:30AM ET, Stanley C. Jordan, M.D., Director of Kidney Transplantation and Transplant Immunology at the Kidney and Pancreas Transplant Center at